- 211 Ongoing Trials in More than 10 Therapeutic Areas
- 106 Sponsors from 13 Countries Have Initiated These 211 Ongoing Trials
- 68 % of On Going Trials with At Least One Location in the USA
- 72 % of On Going Trials with At Least One Location in Europe
- AAV-Based Vectors and Lentiviral Vectors are The Most Widely Used Vectors
- 72 % of Ongoing Trials are Early-Phase Trials (I or I-II)
- Hematological Diseases and Ophthalmological Diseases Are The Most Advanced Therapeutic Areas.